Antibiotika
Vår grupp fokuserar på tidig läkemedelsutveckling. Vi arbetar mot läkemedelsmåltavlor som är av betydelse vid infektionssjukdomar med ett fokus på gram-negativa infektioner, tuberkulos och malaria. I vårt arbete integrerar vi datorbaserad läkemedelsdesign med organisk kemi. Vi arbetar i nära samarbete med mikrobiologer, biokemister och strukturbiologer.
Publikationer
-
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule.
(2022). Frontiers in Molecular Biosciences, . vol. 9 DOI -
Bacterial type I signal peptidase inhibitors-Optimized hits from nature.
(2022). European Journal of Medicinal Chemistry, . vol. 238 DOI -
Towards the sustainable discovery and development of new antibiotics.
(2021). Nature Reviews Chemistry, . vol. 5, ss. 726-749 DOI -
Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors: Synthesis and biological evaluation.
(2021). European Journal of Medicinal Chemistry, . vol. 224 DOI -
ENABLE: an engine for European antibacterial drug discovery and development.
(2021). Nature reviews. Drug discovery, vol. 20, ss. 407-408 DOI -
Computational studies of molecular pre-organization through macrocyclization: Conformational distribution analysis of closely related non-macrocyclic and macrocyclic analogs.
(2021). Bioorganic & Medicinal Chemistry, . vol. 49 DOI -
Synthesis and in vitro biological evaluation of quinolinyl pyrimidines targeting type II NADH-dehydrogenase (NDH-2).
(2022). ACS Infectious Diseases, . vol. 8, ss. 482-498 DOI -
The global preclinical antibacterial pipeline.
(2020). Nature Reviews Microbiology, vol. 18, ss. 275-285 DOI -
Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase.
(2018). European Journal of Medicinal Chemistry, vol. 157, ss. 1346-1360 DOI -
Conformational Analysis of Macrocycles: Comparing General and Specialized Methods.
(2020). Journal of Computer-Aided Molecular Design, vol. 34, ss. 231-252 DOI